Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs
The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) revolutionized the treatment of advanced-stage non-small cell lung cancer (NSCLC). Detected in more than 50% of late-stage lung adenocarcinoma in Asian patients, the EGFR mutation was regarded as a golden mutati...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/4/1141 |
| _version_ | 1827745741417742336 |
|---|---|
| author | Dongyu Li Jingnan Wang Chengming Liu Yuejun Luo Haiyan Xu Yan Wang Nan Sun Jie He |
| author_facet | Dongyu Li Jingnan Wang Chengming Liu Yuejun Luo Haiyan Xu Yan Wang Nan Sun Jie He |
| author_sort | Dongyu Li |
| collection | DOAJ |
| description | The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) revolutionized the treatment of advanced-stage non-small cell lung cancer (NSCLC). Detected in more than 50% of late-stage lung adenocarcinoma in Asian patients, the EGFR mutation was regarded as a golden mutation for Asians. However, resistance to TKIs seems inevitable and severely hinders patients from getting further benefits from treatment. Even though resistance caused by EGFR T790M could be effectively managed by third-generation EGFR-TKIs currently, resistance to third-generation EGFR-TKIs is still a troublesome issue faced by both clinicians and patients. Various efforts have been made to maximize the benefits of patients from EGFR-TKIs therapy. Thus, new requirements and challenges have been posed to clinicians of this era. In this review, we summarized the clinical evidence on the efficacy of third-generation EGFR-TKIs in patients with EGFR-mutated NSCLC. Then, we discussed advancements in sequential treatment aiming to delay the onset of resistance. Moreover, the resistance mechanisms and features were depicted to help us better understand our enemies. Lastly, we put forward future strategies, including recent approaches involving the utilization of antibody drug conjugates against resistance and research directions about shaping the evolution of NSCLC as a core idea in the management of NSCLC. |
| first_indexed | 2024-03-11T05:12:47Z |
| format | Article |
| id | doaj.art-251e3cc21334445aa2f2258fe4e9909e |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T05:12:47Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-251e3cc21334445aa2f2258fe4e9909e2023-11-17T18:27:06ZengMDPI AGBiomedicines2227-90592023-04-01114114110.3390/biomedicines11041141Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIsDongyu Li0Jingnan Wang1Chengming Liu2Yuejun Luo3Haiyan Xu4Yan Wang5Nan Sun6Jie He7Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaThe emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) revolutionized the treatment of advanced-stage non-small cell lung cancer (NSCLC). Detected in more than 50% of late-stage lung adenocarcinoma in Asian patients, the EGFR mutation was regarded as a golden mutation for Asians. However, resistance to TKIs seems inevitable and severely hinders patients from getting further benefits from treatment. Even though resistance caused by EGFR T790M could be effectively managed by third-generation EGFR-TKIs currently, resistance to third-generation EGFR-TKIs is still a troublesome issue faced by both clinicians and patients. Various efforts have been made to maximize the benefits of patients from EGFR-TKIs therapy. Thus, new requirements and challenges have been posed to clinicians of this era. In this review, we summarized the clinical evidence on the efficacy of third-generation EGFR-TKIs in patients with EGFR-mutated NSCLC. Then, we discussed advancements in sequential treatment aiming to delay the onset of resistance. Moreover, the resistance mechanisms and features were depicted to help us better understand our enemies. Lastly, we put forward future strategies, including recent approaches involving the utilization of antibody drug conjugates against resistance and research directions about shaping the evolution of NSCLC as a core idea in the management of NSCLC.https://www.mdpi.com/2227-9059/11/4/1141EGFR-TKIsNSCLClung cancersequential therapyresistant mechanisms |
| spellingShingle | Dongyu Li Jingnan Wang Chengming Liu Yuejun Luo Haiyan Xu Yan Wang Nan Sun Jie He Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs Biomedicines EGFR-TKIs NSCLC lung cancer sequential therapy resistant mechanisms |
| title | Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs |
| title_full | Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs |
| title_fullStr | Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs |
| title_full_unstemmed | Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs |
| title_short | Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs |
| title_sort | making the best use of available weapons for the inevitable rivalry resistance to egfr tkis |
| topic | EGFR-TKIs NSCLC lung cancer sequential therapy resistant mechanisms |
| url | https://www.mdpi.com/2227-9059/11/4/1141 |
| work_keys_str_mv | AT dongyuli makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT jingnanwang makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT chengmingliu makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT yuejunluo makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT haiyanxu makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT yanwang makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT nansun makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis AT jiehe makingthebestuseofavailableweaponsfortheinevitablerivalryresistancetoegfrtkis |